Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia
Leukemia, Hairy Cell
Sialic Acid Binding Ig-like Lectin 2
Moxetumomab pasudotox at doses up to 50 μg/kg QOD ×3 has activity in relapsed/refractory HCL and has a safety profile that supports further clinical development for treatment of this disease.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency